Exclusive Interview with ASBM Released Ahead of Upcoming Biosimilars Conference
Exclusive interview with expert speaker from ASBM
Partner content/ Patients/ Press releases
ssapal@smi-online.co.uk
biosimilars, healthcare, NHS, Patents, regulation
0 Comment
Exclusive interview with expert speaker from ASBM
George Underwood
EPO, Europe, Innovation, Patents, UK
0 Comment
Market Access/ Views & Analysis/ Views and analysis
Linda Banks
Legal, Patents, pharma law, plausibility
0 Comment
Pharma needs clarity from the Supreme Court on whether the whole scope of a patent claim must be plausible at the time of the application.
Market Access/ Views and analysis
Linda Banks
China, Intellectual property, IP, Patents, pharma in China
0 Comment
China has become more accepting of Western medicines and sees the value of a strong patenting process, opening the door for more foreign trade and mutual benefits.
News/ News/ Pfizer/ Pharma Market Access/ R&D
Andrew McConaghie
Actavis, BIA, Patents, Pfizer, UK biotech
0 Comment
Articles/ Deep Dive/ Pharma Market Access/ Views and analysis
Linda Banks
access to medicines, drug patents, Patents, pharma patents
0 Comment
Extending patents is restricting patients’ access to the treatments they need.
Articles/ R&D/ US/ Views and analysis
Marco Ricci
generics, Intellectual property, IP, Law, Legal, Patents
0 Comment
IP management can protect pharma companies’ investments and future R&D.
Articles/ Pharma Market Access/ US/ Views and analysis
Marco Ricci
Abbreviated New Drug Applications, ANDA, generics, Intellectual property, IP, litigation, Patents
0 Comment
Sheila Swaroop and Kaitlin Heinen examine the findings of a recent report.